Camp4 Therapeutics Corporation
CAMP
$4.69
-$0.31-6.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.50M | 3.80M | 3.01M | 1.51M | 652.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.50M | 3.80M | 3.01M | 1.51M | 652.00K |
| Cost of Revenue | 38.20M | 39.84M | 40.19M | 39.23M | 38.83M |
| Gross Profit | -34.70M | -36.04M | -37.18M | -37.72M | -38.18M |
| SG&A Expenses | 17.36M | 17.28M | 16.50M | 15.59M | 14.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.56M | 57.12M | 56.69M | 54.82M | 53.74M |
| Operating Income | -52.06M | -53.32M | -53.68M | -53.31M | -53.09M |
| Income Before Tax | -80.40M | -53.40M | -51.78M | -51.77M | -51.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.40 | -53.40 | -51.78 | -51.77 | -51.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.40M | -53.40M | -51.78M | -51.77M | -51.79M |
| EBIT | -52.06M | -53.32M | -53.68M | -53.31M | -53.09M |
| EBITDA | -50.42M | -51.63M | -51.99M | -51.63M | -51.39M |
| EPS Basic | -2.54 | -2.56 | -26.20 | -51.58 | -77.53 |
| Normalized Basic EPS | -1.58 | -1.59 | -16.38 | -32.24 | -48.46 |
| EPS Diluted | -2.54 | -2.56 | -26.20 | -51.58 | -77.53 |
| Normalized Diluted EPS | -1.58 | -1.59 | -16.38 | -32.24 | -48.46 |
| Average Basic Shares Outstanding | 121.45M | 84.84M | 58.12M | 38.44M | 18.76M |
| Average Diluted Shares Outstanding | 121.45M | 84.84M | 58.12M | 38.44M | 18.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |